Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 1/2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 41OTHER 2NETWORK 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

toripalimab 1naxitamab 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Has announcements × Clear all
NCT01757626 2026-01-07

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
186 enrolled 1 FDA
CNS

Neuroblastoma

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
401 enrolled 1 FDA
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡